Abstract
▴ Solifenacin is a bladder-selective, muscarinic (M1 and M3) receptor antagonist. In animal studies, the selectivity of solifenacin for the bladder over the salivary glands was greater than that of tolterodine, oxybutynin, darifenacin or atropine.
▴ In large, 12-week, randomised, double-blind, multicentre clinical trials, solifenacin 5 and 10mg once daily improved symptoms of overactive bladder syndrome (OAB) [urinary urgency, frequency, incontinence and nocturia] and increased functional bladder capacity to a significantly greater extent than placebo.
▴ Solifenacin 5 or 10mg once daily was noninferior to tolterodine extended release (ER) 4mg daily for improving urinary frequency and had significantly greater efficacy than tolterodine ER for improving other symptoms of OAB (episodes of urgency, incontinence and urge incontinence) and increasing functional bladder capacity.
▴ At least half of all patients receiving solifenacin who were incontinent at baseline were continent by study end in the three comparative studies reporting this parameter.
▴ Health-related quality of life was significantly improved with once-daily solifenacin 5 or 10mg versus placebo, as assessed in two 12-week double-blind studies; the improvement was maintained during a 40-week extension study.
▴ Solifenacin was generally well tolerated; the most frequently reported adverse events were dry mouth, constipation and blurred vision.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurology 2004; 3(1): 46–53
Herbison P, Hay-Smith J, Ellis G, et al. Effectiveness of cholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003; 326: 841–4
Nitti VW. Clinical impact of overactive bladder. Reviews in Urology 2002; 4(Suppl. 4): S2–6
Debruyne FMJ, Heesakkers JPFA. Clinical and socioeconomic relevance of overactive bladder. Urology 2004; 63 (3 Suppl. 1): 42–4
Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000 Jul; 6 (11 Suppl.): S580–90
Wein AJ. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opin Investig Drugs 2001 Jan; 10(1): 65–83
Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology 2002 Nov; 60 (5 Suppl. 1): 82–8; discussion 88–9
Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000 May; 55(5A Suppl.): 33–46; discussion 50
Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005 Mar; 47(3): 376–84
Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn-Schmiedebergs Arch Pharmacol 2002 Aug; 366(2): 97–103
Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004 May 25; 492(2–3): 243–50
Kobayashi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci 2004 Jan 2; 74(7): 843–53
Robinson D, Cardozo L. The emerging role of solifenacin in the treatment of overactive bladder. Expert Opin Investig Drugs 2004 Oct; 13(10): 1339–48
Smulders RA, van Alphen W, Visser J, et al. Multiple dosing with YM905, a novel, bladder-selective antimuscarinic, in healthy men: safety and tolerability and pharmacokinetics. 32nd Annual Meeting of the International Incontinence Society; 2002 Aug 27–30; Heidelberg
Kuipers ME, Krauwinkel WJJ, Mulder H, et al. Solifenacin demonstrates high absolute bioavailability in healthy men. Drugs RD 2004; 5(2): 73–81
Uchida T, Krauwinkel WJ, Mulder H, et al. Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial. Br J Clin Pharmacol 2004 Jul; 58(1): 4–7
Krauwinkel WJ, Smulders RA, Mulder H, et al. Effect of age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther 2005 May; 43(5): 227–38
Smith N, van Zijtveld J, Swart PJ, et al. Co-administration of ketoconazole, a potent CYP3A4 inhibitor, does not affect safety or tolerability of YM 905. 32nd Annual Meeting of the International Incontinence Society; 2002 Aug 27–30; Heidelberg
VESIcare® (solifenacin succinate) prescribing information. Paramus (NJ): Yamnouchi Pharma America, Inc. and Research Triangle Park (NC): GlaxoSmithKline, 2004
Chapple CR, Martinez-Garcia, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome; results of the STAR trial. Eur Urol 2005; 48(3): 464–70
Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004 Feb; 93(3): 303–10
Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily muscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919–24
Gittelman M, Chu FM, Klimberg I, et al. Two randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter studies assess the efficacy and safety of daily oral administration of 10 mg YM905 versus placebo in male and female subjects with overactive bladder. J Urol 2003 Apr; 169 (Suppl.): 349
Kelleher CJ, Cardozo L, Chapple CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005 Jan; 95(1): 81–5
Lucente V, Swift S. Urgency episodes were statistically reduced with solifenacin treatment for overactive bladder. 2004 Joint Scientific Meeting. The American Urogynecologic Society and The Society of Gynecologic Surgeons; 2004 July 29–31; San Diego, CA
Garely AD. Solifenacin succinate once daily is superior to placebo in all major overactive bladder symptoms in four trials: results in women. Obstet Gynecol 2004 Apr; 103(Suppl. 4): 129
Kaufman J, Knapp P, Siami P, et al. YM905 10 mg increases the proportion of male and female patients with overactive bladder who become continent. J Am Geriatr Soc 2003 Apr; 51 (Suppl.): 100
Chapple CR, Arano P, Bosch JLHR, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004 Jan; 93(1): 71–7
Yamnouchi Pharma Ltd. Vesicare® 5mg and 10mg film-coated tablets. Special Product Characteristics [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2004 Nov 26]
Acknowledgements
At the request of the journal, Astellas Pharma Inc. provided a non-binding review of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Simpson, D., Wagstaff, A.J. Solifenacin in Overactive Bladder Syndrome. Drugs Aging 22, 1061–1069 (2005). https://doi.org/10.2165/00002512-200522120-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200522120-00005